Antibe Therapeutics Inc(Pre-Merger) ATBPF

Guesses on the next big news release?

[markymark11]

Below is a summary of clinical and corporate activities identified from the Shareholder Letter released on January 11, 2021:

• Phase 3 enabling animal studies - 8 completed, 2 in progress
• CMC and tablet production - in progress
• Submission of FDA IND application - completed and approved
• Initiate Phase 3 trials - anticipated to begin H2 calendar 2021
• Enhanced 6-week AME study to provide pharmacokinetic data and de-risk dose selection - set to begin Q1 calendar 2021
• ATB-352 - currently in IND-enabling studies, with human trials slated for late calendar 2021 (per March 2021 Corporate Presentation)
• IBD candidate identified
• Launch of large market partnering - in progress
• Unify IP - in progress
• Upgrade to OTC QX - completed Feb 16

Subsequent to January 11, 2021 Shareholder Letter, the following announcements have been made:

• Nuance Deal - Feb 9
• Bought Deal - Feb 17/24
• Investor conferences - Mar 8-17
• FDA clearance of IND application - Mar 29

Guesses on what's the next big news release? I personally would like an update on the IP unification, and the AME study. I have a feeling they won't say anything about the AME study though. Antibe is a bit stingy with the news releases. Many biotech companies would've had an announcement along the lines of "Antibe Submits Investigational New Drug (IND) Application with U.S. FDA" before the announcement of the IND approval.

Of course, I certainly wouldn't complain if the next news release was Pfizer buying us out for $4 billion USD....

[MrMugsy]

I am personally hoping for a new drug to be announced. It isn't about the present share price (for me) but its about creating value for a Big Pharma partnership. If they can quickly come up with a potential Alzheimer's candidate than we likely have one for Parkinson's and other brain related indications (like Central Sleep Apnea and a general anti-aging drug for brain cells) as well.&

[Nick80]

*If they can quickly come up with a potential Alzheimer's candidate than we likely have one for Parkinson's and other brain related indications (like Central Sleep Apnea and a general anti-aging drug for brain cells) as well.  This could become a once-a-day along with Aspirin for everyone over 50.  See how we get into the wellness market?  Skru the vitamin market - we've

[mrv2000]

that Kim Kadashian has voluntered to paticipate in a special study,  on ulser treatments, caused by kayne west

[MrMugsy]

I've been saying this for a while now. One of ATE's strategic directions is to create new drugs and to show how quickly they can do it with new capabilities offered through their academic partner. We had an IBD drug called ATB-429 and we trashed it for a new design (recently). Dan also said they are going to work on new drugs ... specifically a newer molecule to go head-to-head with 340

[Marky1]

MarkyMark...Great information...Thank u....like your name!

[markymark11]

Haha thanks Marky. I like your username as well. I guess great minds think alike!

[WalkOverTheStrt]

BPs will add value to Antibe's other pipeline drugs when at a min there is a completed PH1 study (start slate for late 2021...). Mgmt didn't do us shareholders many favors by slow rolling Oten (pre covid it was delyaed multiple times) and not advancing other pipeline drugs to humans. Now antibe is in catch up mode to make the hydrogen sulfide seen as a platform to BPs. Well animal